Fibrinogen Guarenas, an abnormal fibrinogen with an Aα-chain truncation due to a nonsense mutation at Aα 467 Glu (GAA) → stop (TAA)

Thrombosis Research

Volumn 118, Issue 5, 2006, Pages 637-650

  Marchi, Rita ^a   Carvajal, Zoila ^a   Meyer, Michael ^b   Soria, Jeannette ^c   Ruiz Saez, Arlette ^d   Arocha Piñango, Carmen Luisa ^a   Weisel, John W ^e  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b UNIVERSITY OF APPLIED SCIENCES JENA   (Germany)

^c HÔTEL DIEU   (France)

^d Banco Metropolitano de Sangre del Distrito Capital   (Venezuela)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clot structure; Dysfibrinogenemia; Fibrinolysis; Rheological properties

Indexed keywords

ALBUMIN; DIMER; FIBRIN; FIBRINOGEN; PLASMIN; PLASMINOGEN; POLYMER; THIOL GROUP; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLEEDING TENDENCY; CONFOCAL MICROSCOPY; DIMERIZATION; DYSFIBRINOGENEMIA; FIBRIN CLOT; FIBRIN POLYMERIZATION; FIBRINOGEN GUARENAS; FIBRINOLYSIS; FLOW RATE; HUMAN; NONSENSE MUTATION; POROSITY; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOSIS; TURBIDITY;

AFIBRINOGENEMIA; CODON, NONSENSE; FIBRINOGENS, ABNORMAL; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33748785169     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.10.016     Document Type: Article

References (53)

1. Blombäck B. Fibrinogen and fibrin-proteins with complex roles in haemostasis and thrombosis. Thromb Res 83 (1996) 1-75
2. Doolittle R.F. Fibrinogen and fibrin. Annu Rev Biochem 53 (1984) 195-229
3. Blombäck B., Hessel B., Hogg D., and Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 275 (1978) 501-505
4. Olexa S.A., and Budzynski A.Z. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci U S A 77 (1980) 1374-1378
5. Mosesson M.W. Fibrinogen and fibrin polymerization: appraisal of the binding events that accompany fibrin generation and fibrin clot assembly. Blood Coagul Fibrinolysis 8 (1997) 257-267
6. Veklich Y.I., Gorkun O.V., Medved L.V., Nieuwenhuizen W., and Weisel J.W. Carboxy-terminal portions of the α chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated αC fragments on polymerization. J Biol Chem 268 (1993) 13577-13585
7. Gorkun O.V., Veklich Y.I., Medved L.V., Henschen A.H., and Weisel J.W. Role of the αC domains of fibrin in clot formation. Biochemistry 33 (1994) 6986-6997
8. Martinez J. Congenital dysfibrinogenemia. Curr Opin Hematol 4 (1997) 357-365
9. Brennan S.O., Fellowes A.P., and George P.M. Molecular mechanisms of hypo- and afibrinogenemia. Ann N Y Acad Sci 936 (2001) 91-100
10. Koopman J., and Haverkate F. Hereditary variants of human fibrinogens. In: Bloom A.L., Forbes C.D., Tomas D.P., and Tuddenham E.G.D. (Eds). Haemostasis and thrombosis. Ed 3 (1994), Churchill Livingstone, Edinburgh, UK 515
11. Ebert R.F. Index of variant human fibrinogens (1994), CRC, Boca Raton, FL Edition
12. Maekawa H., Yamazumi K., Muramatsu S., Kaneko M., Hirata H., Takahashi N., et al. An Aα Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, Fibrinogen Caracas II, characterized by impaired fibrin gel formation. J Biol Chem 266 (1991) 11575-11581
13. Marchi R., Lundberg U., Grimbergen J., Koopman J., Torres A., Bosch N., et al. Fibrinogen Caracas V, an abnormal fibrinogen with an Aα 532 Ser → Cys substitution associated with thrombosis. Thromb Haemost 84 (2000) 263-270
14. Koopman J., Haverkate F., Grimbergen J., Lord S.T., Mosesson M., DiOrio J.P., et al. Molecular basis for fibrinogen Dusart (Aα 554 Arg → Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 91 (1993) 1637-1643
15. Koopman J., Haverkate F., Grimbergen J., Egbring R., and Lord S.T. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids Aα 461-610 (Lys 461 AAA → stop TAA). Blood 80 (1992) 1972-1979
16. Tsurupa G., and Medved L. Fibrinogen αC domains contain cryptic plasminogen and t-PA binding sites. Ann N Y Acad Sci 936 (2001) 328-330
17. Medved L., Tsurupa G., and Yakovlev S. Conformational changes upon conversion of fibrinogen into fibrin. The mechanisms of exposure of cryptic sites. Ann N Y Acad Sci 936 (2001) 185-204
18. Niewenhuizen W. Sites in fibrin involved in the acceleration of plasminogen activation by t-PA. Possible role of fibrin polymerization. Thromb Res 75 (1994) 343-347
19. Lefebvre P., Velasco P.T., Dear A., Lounes K.C., Lord S.T., Brennan S.O., et al. Severe hypodysfibrinogenemia in compound heterozygotes of fibrinogen AαIVS4 + 1G > T mutation and an AαGln328 truncation (Fibrinogen Keokuk). Blood 103 (2004) 2571-2576
20. Ridgway H.J., Brennan S.O., Gibbons S., and George P.M. Fibrinogen Lincoln: a new truncated α chain variant with delayed clotting. Br J Haematol 93 (1996) 177-184
21. Collen A., Maas A., Kooistra T., Lupu F., Grimbergen J., Haad F.J., et al. Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Aα-chain, alters endothelial capillary tube formation. Blood 97 (2001) 973-980
22. Furlan M., Steinmann C., Jungo M., and Lämmle B. Binding of calcium ions and their effect on clotting of fibrinogen Milano III, a variant with truncated Aα-chains. Blood Coagul Fibrinolysis 7 (1996) 331-335
23. Ridgway H.J., Brennan S.O., Faed J.M., and George P.M. Fibrinogen Otago: a major α chain truncation associated with severe hypofibrinogenemia and recurrent miscarriage. Br J Haematol 98 (1997) 632-639
24. Margaglione M., Vecchione G., Santacroce R., D'Angelo F., Casetta B., Papa M.L., et al. A Frameshift mutation in the human fibrinogen Aα-chain gene (Aα[499]Ala frameshift stop) leading to dysfibrinogen San Giovanni Rotondo. Thromb Haemost 86 (2001) 1483-1488
25. Marchi R., Meyer M., de Bosch N., Soria J., and Arocha-Piñango C.L. Biophysical Characterization of Fibrinogen Caracas I with an Aα-chain truncation at Aα 466 Ser. Identification of the mutation and biophysical characterization of properties of clots from plasma and purified fibrinogen. Blood Coagul Fibrinolysis 15 (2004) 285-293
26. Homer V.M., Mullin J.L., Brennan S.O., Barr A., and George P.M. Novel Aα chain truncation (fibrinogen Perth) resulting in low expression and impaired fibrinogen polymerization. J Thromb Haemost 1 (2003) 1245-1250
27. Brennan S.O., Homer V.M., Ockelford P., and George P.M. Low expression of truncated Aα chain variant in circulating fibrinogen. Thromb Haemost 88 (2002) 533-534
28. Blombäck B., and Blombäck M. Purification of human and bovine fibrinogen. Ark kemi 10 (1956) 415-443
29. Galanakis D.K., Henschen A., Peerschke E.I., and Kehl M. Fibrinogen Stony Brook, a heterozygous Aα 16 Arg → Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibrin assembly. Clin Investig 84 (1989) 295-304
30. Schägger H., and Von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166 (1987) 368-379
31. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
32. Soria J., Soria C., and Girard M.L. Troubles de la fibrino-formation. Techniques d' appréciation du premier stade. Pathol Biol 20 (1972) 315-321
33. Lee K.N., Birckbichler P.J., and Patterson Jr. M.K. Colorimetric assay of blood coagulation factor XIII in plasma. Clin Chem 34 (1988) 906-910
34. Song Y.C., Sheng D., Taubenfeld S.M., and Matsueda G.R. A microtiter assay for factor XIII using fibrinogen and biotinylcadaverine as substrates. Anal Biochem 223 (1994) 88-92
35. Niwa K., Takebe M., Sugo T., Kawata Y., Mimuro J., Asakura S., et al. A γ Gly-268 to Glu substitution is responsible for impaired fibrin assembly in a homozygous dysfibrinogen Kurashiki I. Blood 87 (1996) 4686-4694
36. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci 76 (1979) 4350-4354
37. Marchi R., Mirshahi S.S., Soria C., Mirshahi M., Zohar M., Collet J.P., et al. Thrombotic dysfibrinogenemia: fibrinogen "Caracas V" relation between very tight fibrin network and defective clot degradability. Thromb Res 99 (2000) 187-193
38. Blombäck B., Carlsson K., Hessel B., Liljeborg A., Procyk R., and Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 997 (1989) 96-110
39. Blombäck B., and Okada M. Fibrin gel structure and clotting time. Thromb Res 25 (1982) 51-70
40. Lijnen H.R., Soria J., Soria C., Collen D., and Caen J.P. Dysfirinogenemia (Fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 51 (1984) 108-109
41. Janmey A. A torsion pendulum for measurement of the viscoelasticity of biopolymers and its application to actin networks. J Biochem Biophys Methods 22 (1991) 41-53
42. Lundberg U.G., Rodriguez S., Marchi R., Ruiz-Sáez A., and Arocha-Piñango C.L. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization. Thromb Res 78 (1995) 95-106
43. Carr Jr. M.E., and Carr S.L. Fibrin structure and concentration alter clot elastic modulus but do not alter platelet mediated force development. Blood Coagul Fibrinolysis 6 (1995) 79-86
44. Siebenlist K.R., Mosesson M.W., DiOrio J.P., Soria J., Soria C., and Caen J.P. The polymerization of fibrinogen Dusart (Aα 554 Arg → Cys) after removal of carboxy terminal regions of the Aα-chains. Blood Coagul Fibrinolysis 4 (1993) 61-65
45. Collet J.P., Soria J., Mirshahi M., Hirsch M., Dagonnet F.B., Caen J., et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 82 (1993) 2462-2469
46. Collet J.P., Woodhead J.L., Soria J., Soria C., Mirshahi M., Caen J.P., et al. Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots. Biophys J 70 (1996) 500-510
47. Carrell N., Gabriel D.A., Blatt P.M., Carr M.E., and Mc Donagh J. Hereditary dysfibrinogenemia in a patient with thrombotic disease. Blood 62 (1983) 439-447
48. Wada Y., and Lord S.T. A correlation between thrombotic disease and a specific fibrinogen abnormality (Aα 554 Arg → Cys) in two unrelated kindred Dusart and Chapel Hill III. Blood 84 (1994) 3709-3714
49. Mosesson M.W., Siebenlist K.R., Hainfeld J.F., Wall J.S., Soria J., Soria C., et al. The relationship between the fibrinogen D domain self-association/cross-linking site (γXL) and the fibrinogen Dusart abnormality (Aα R554C-Albumin). Clues to thrombophilia in the "Dusart syndrome". J Clin Invest 97 (1996) 2342-2350
50. Koopman J., Haverkate F., Lord S.T., Grimbergen J., and Mannucci P.M. Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of Bβ 68 Ala → Thr. J Clin Invest 90 (1992) 238-244
51. 44 → Cys) form disulfide-linked fibrinogen-albumin complexes. Proc Natl Acad Sci U S A 89 (1992) 3478-3482
52. Engesser L., Koopman J., de Munk G., Haverkate F., Nováková I., Verheijen J.H., et al. Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA. Thromb Haemost 60 (1988) 113-120
53. Liu C.Y., Koehn J.A., and Morgan F.J. Characterization of fibrinogen New York I. A dysfunctional fibrinogen with a deletion of Bβ (9-72) corresponding to exon II of the gene. J Biol Chem 260 (1985) 4390-4396